Moderna, INC Schedule 13G passive stakes

Capital World Investors has reported a beneficial ownership of 22,276,996 shares, representing 5.6% of Moderna, Inc.'s common stock.

Baillie Gifford & Co has updated its Schedule 13G filing, reporting beneficial ownership of 18,206,778 shares of Moderna, Inc. common stock, representing 4.6% of the class.

Vanguard Capital Management has disclosed beneficial ownership of 25,933,824 shares, representing 6.53% of Moderna Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported zero beneficial ownership in Moderna Inc. common stock following an internal realignment effective January 12, 2026.

Baillie Gifford & Co. has filed an amendment to its Schedule 13G, reporting a 5.27% beneficial ownership stake in Moderna, Inc. as of December 31, 2025.

FMR LLC and its affiliates, including Abigail P. Johnson, reported beneficial ownership of 10.6% of Moderna Inc.'s common stock as of January 30, 2026.

FMR LLC and its affiliates, including Abigail P. Johnson, have reported a 7.2% beneficial ownership stake in Moderna Inc. as of December 31, 2025.

FMR LLC and its affiliates, including Abigail P. Johnson, have reported a 3.2% beneficial ownership stake in Moderna Inc., totaling 12,304,297.37 shares as of September 30, 2025.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have reported a beneficial ownership of 5.5% in Moderna Inc., totaling over 21 million shares, as of March 31, 2025.

Baillie Gifford & Co has filed an Amendment No. 5 to Schedule 13G, disclosing its beneficial ownership of 6.45% of Moderna, Inc.'s Common Stock as of March 31, 2025.

Baillie Gifford & Co., a UK-based investment adviser, has filed an Amendment No. 4 to Schedule 13G, reporting a 10.1% beneficial ownership in Moderna, Inc. as of December 31, 2024.